- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03833869
Assisted Hatching in Frozen Blastocysts
June 6, 2019 updated by: Hadas Ganer Herman, Wolfson Medical Center
The Effect of Assisted Hatching on Implantation Rate in Frozen Blastocyst Transfer - a Prospective Randomized Controlled Study
The current study aims to assess the effect of assisted hatching on the implantation rate of frozen blastocytes.
Study Overview
Detailed Description
The Zona Pellucida protects the ovum from the penetration of multiple sperm, and from mechanical and physiological damage until the fertilized ovum reaches the uterus.
Subsequently, spontaneous hatching occurs, and enables the embryo to attach to the endometrium.
The technique of assisted hatching was originally investigated as a means to improve implantation in cases of zona hardening, and is commonly performed in 3-day embryos.
In the current study, the investigators aim to investigate the effect of assisted hatching on 5-day frozen embryos.
Study Type
Interventional
Enrollment (Anticipated)
84
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
H̱olon, Israel
- Recruiting
- Edith Wolfson Medical Center
-
Contact:
- Hadas Ganer Herman, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 39 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- In-vitro fertilization patients at the investigators' institution, intended to undergo a transfer of a frozen five-day embryo (blastocyte)
- 18 to 39 years old
- First to third treatment cycle
- Patient has previously had a maximum of four embryos transferred.
Exclusion Criteria:
- Over 40 years old
- Congenital or acquired uterine malformations
- Hydrosalpinx
- Chronic autoimmune diseases
- Embryo intended to be undergo preimplantation genetic diagnosis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Assisted hatching
Five-day frozen embryos will undergo assisted hatching prior to embryo transfer
|
Controlled hatching of the zona pellucida in the laboratory prior to embryo transfer
|
NO_INTERVENTION: Control
Five-day frozen embryos will not undergo any additional procedures prior to embryo transfer
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Implantation rate
Time Frame: Five to six weeks following embryo transfer
|
Number of gestational sacs demonstrated on ultrasound divided by the number of embryos transferred (expressed as percentage)
|
Five to six weeks following embryo transfer
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Chemical pregnancy
Time Frame: Five to six weeks following embryo transfer
|
Increase and subsequent decrease in beta HCG levels with no evidence of gestational sac on ultrasound
|
Five to six weeks following embryo transfer
|
Early spontaneous abortion
Time Frame: Up to 15 weeks from embryo transfer
|
Spontaneous abortion of pregnancy during the first trimester of pregnancy
|
Up to 15 weeks from embryo transfer
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
March 1, 2019
Primary Completion (ANTICIPATED)
March 1, 2020
Study Completion (ANTICIPATED)
March 1, 2020
Study Registration Dates
First Submitted
February 6, 2019
First Submitted That Met QC Criteria
February 6, 2019
First Posted (ACTUAL)
February 7, 2019
Study Record Updates
Last Update Posted (ACTUAL)
June 11, 2019
Last Update Submitted That Met QC Criteria
June 6, 2019
Last Verified
February 1, 2019
More Information
Terms related to this study
Other Study ID Numbers
- 0020-19-WOMC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ART
-
Assiut UniversityWithdrawn
-
Karadeniz Technical UniversityCompleted
-
Instituto Valenciano de Infertilidade de LisboaCompleted
-
Wolfson Medical CenterUnknown
-
NYU Langone HealthCompleted
-
IVI SevillaCompleted
-
Peking University Third HospitalUnknown
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaboratorsNot yet recruiting
-
Zagazig UniversityRecruitingEmbryo Implantation | ARTEgypt
-
Istituto Clinico HumanitasCompletedChild Development | ARTItaly
Clinical Trials on Assisted hatching
-
KU LeuvenCompletedPlacenta; ImplantationBelgium
-
Reproductive Medicine Associates of New JerseyNot yet recruitingInfertilityUnited States
-
IRCCS San RaffaeleCompleted
-
University Hospital, GhentCompleted
-
Shady Grove Fertility Reproductive Science CenterCompleted
-
Shaare Zedek Medical CenterTerminatedPregnancy | Placenta; Implantation | Complications Associated With Artificial FertilizationIsrael
-
Kasr El Aini HospitalUnknownRecurrent Implantation Failure
-
Daniel Collado-MateoAsociación Dame La PataRecruitingWork Related Stress | Occupational GroupsSpain
-
Daniel Collado-MateoPurina España (Reg. Trademark of Nestle S.A.)Enrolling by invitationEating Disorders | Eating Disorders in Adolescence | Anorexia Nervosa/BulimiaSpain